INFLUENZA VACCINATION OF CHILDREN OF PRESCHOOL AGE IN THE RUSSIAN FEDERATION: COST-EFFECTIVENESS OF QUADRIVALENT VACCINE

QR Code

INFLUENZA VACCINATION OF CHILDREN OF PRESCHOOL AGE IN THE RUSSIAN FEDERATION: COST-EFFECTIVENESS OF QUADRIVALENT VACCINE

According to requirements of WHO, the trivalent influenza vaccines (TIV) have to contain antigens of two influenza A strains (A/H1N1, A/H3N2) and one influenza B strain which can be presented by antigens of a virus of lineages Yamagata or Victoria. In a season of 2017/2018 the discrepancy of the vac...

Full description

Saved in:

Bibliographic Details
Main Authors:	A. V. Rudakova, D. M. Danilenko, D. A. Lioznov, L. S. Karpova, S. M. Kharit, E. V. Mikitenko, A. N. Uskov, A. S. Kolbin, L. N. Konovalova, Yu. V. Lobzin
Format:	Article
Language:	Russian
Published:	Journal Infectology 2019-03-01
Series:	Журнал инфектологии
Subjects:	influenza vaccination quadrivalent vaccine cost-effectiveness
Online Access:	https://journal.niidi.ru/jofin/article/view/857
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The averted costs due to influenza vaccination with trivalent and quadrivalent vaccines
by: S. M. Kharit, et al.
Published: (2017-06-01)

Assessment of Reactogenicity and Immunogenicity of the Quadrivalent Live Attenuated Influenza Vaccine
by: D. A. Lioznov, et al.
Published: (2018-06-01)

Results of Clinical Trials of the First Russian 4-valent Flu Vaccine
by: D. A. Lioznov
Published: (2018-09-01)

Evaluation of Seasonal Inactivated Influenza Vaccines Prophylactic Efficacy
by: K. V. Zhdanov, et al.
Published: (2022-11-01)

Immunisation of young children against influenza — evidence review
by: V. A. Bulgakova, et al.
Published: (2022-10-01)

Results of a clinical study of the influenza tetravalent inactivated subunit adjuvant vaccine Grippol Quadrivalent in children aged 6 months to 5 years (inclusive)
by: Viktor V. Romanenko, et al.
Published: (2024-07-01)

The immunogenicity and safety of an inactivated quadrivalent influenza vaccine and a 23-valent pneumococcal polysaccharide vaccine in individuals with chronic diseases
by: Wanqin Tang, et al.
Published: (2025-08-01)

Influenza burden averted with a cell-based quadrivalent seasonal influenza vaccine compared with egg-based quadrivalent seasonal influenza vaccine
by: Ian McGovern, et al.
Published: (2024-12-01)

Review of Grippol Family Vaccine Studies and Modern Adjuvant Development
by: A. V. Karaulov, et al.
Published: (2019-09-01)

Cost-effectiveness of quadrivalent human papillomavirus vaccination in adolescent girls
by: A. V. Rudakova, et al.
Published: (2016-11-01)

Vaccination against influenza in children – how it goes this season
by: V. A. Bulgakova, et al.
Published: (2021-06-01)

The Relevance of Tetravalent Influenza Vaccines. World experience
by: A. D. M. E. Osterhaus
Published: (2018-09-01)

About influenza and flu vaccination: opinion the students’ medical school V.V. Balzhieva, L.A. Khlebnik
by: V. V. Balzhieva, et al.
Published: (2025-06-01)

Modelling the population-level benefits and cost-effectiveness of cell-based quadrivalent influenza vaccine for children and adolescents aged 6 months to 17 years in the US
by: Stephen I. Pelton, et al.
Published: (2024-12-01)

POST-VACCINATION IMMUNE RESPONCE IN SERONEGATIVE TO INFLUENZA VIRUS HIV-INFECTED PATIENTS
by: R. G. Yapparov, et al.
Published: (2018-04-01)

Vaccination and treatment of influenza: achievements and challenges
by: N. I. Briko, et al.
Published: (2021-06-01)

Disparities in Seasonal Influenza Vaccination in Europe
by: Katinka M. Giezeman‐Smits, et al.
Published: (2025-07-01)

Relationship between parental vaccine literacy and their willingness to vaccinate children against influenza in china
by: Zhuoran Huang, et al.
Published: (2025-12-01)

ТHE LEVEL OF ANTIBODIES TO THE INFLUENZA VIRUS IN PREGNANT WOMEN VACCINATED WITH SUBUNIT VACCINE
by: M. P. Kostinov, et al.
Published: (2018-01-01)

Comparable effectiveness of MF59®-adjuvanted and high-dose quadrivalent inactivated influenza vaccines for prevention of test-confirmed influenza during the 2022-2023 influenza season
by: Mahrukh Imran, et al.
Published: (2025-10-01)

Inactivated recombinant influenza vaccine: the promising direction for the next generation of influenza vaccine
by: Hua Shi, et al.
Published: (2024-12-01)

A preliminary exploration of influenza-like illness surveillance and influenza vaccination in Jing’an District of Shanghai， 2017‒2023
by: HUA Ruijue, et al.
Published: (2025-04-01)

Exploring influenza vaccination coverage and barriers to influenza vaccine uptake among preschool children in Fuzhou in 2022: a cross-sectional study
by: Haimei Jia, et al.
Published: (2025-07-01)

POTENTIAL OF THE RUSSIAN FEDERATION IN EXPORTS OF ANTI-INFLUENZA VACCINES IN LATIN AMERICAN COUNTRIES
by: V. P. Trukhin, et al.
Published: (2019-01-01)

RESULTS OF THE IMMUNIZATION ACCORDING TO THE NATIONAL CALENDAR ASSOCIATED WITH VACCINATION AGAINST INFLUENZA IN CHILDREN WITH SOMATIC DISORDERS AND IMMUNODEFICIENCY
by: S. M. Kharit, et al.
Published: (2014-01-01)

Evaluation of the Epidemiological Effectiveness of a Quadrivalent Inactivated Split Influenza Vaccine in the 2023–2024 flu season
by: R. V. Polibin, et al.
Published: (2025-01-01)

Real-world effectiveness of live attenuated influenza vaccines (LAIV) and inactivated influenza vaccines (IIV) in children from 2003 to 2023: a systematic literature review and network meta-analysis
by: Anke L. Stuurman, et al.
Published: (2025-12-01)

Trust in the Public Health System and Seasonal-Influenza Vaccination
by: Marian Vasile, et al.
Published: (2024-02-01)

Consensus Guidelines for Influenza Vaccination in Patients with Diabetes
by: Sukamto Koesnoe, et al.
Published: (2024-04-01)

Topical Issues of Influenza Vaccine Prevention
by: Firuza Ch. Shakhtakhtinskaya, et al.
Published: (2021-10-01)

Analysis of Batch to Batch Consistency of a Locally Produced Influenza Vaccine for the 2017–2018 Influenza Season
by: P. V. Demidova, et al.
Published: (2018-06-01)

Humoral immunity in elderly persons vaccinated against influenza shortly before cancellation of COVID-19 pandemic
by: S. V. Iushkova, et al.
Published: (2025-03-01)

Mapping and ranking outcomes for the evaluation of seasonal influenza vaccine efficacy and effectiveness: a delphi study
by: Chiara de Waure, et al.
Published: (2024-12-01)

Influenza and Pneumococcal Vaccination of Healthcare Workers during a Pandemic Reduces the Risk and Severity of COVID-19 in Vaccinated
by: M. P. Kostinov, et al.
Published: (2023-09-01)

Determinants of Accepting or Rejecting Influenza Vaccination—Results of a Survey Among Ligurian Pharmacy Visitors During the 2023/2024 Vaccination Campaign
by: Daniela Amicizia, et al.
Published: (2025-05-01)

Cost-Effectiveness of Quadrivalent Human Papillomavirus Vaccination in Adolescent Girls in Russian Federation
by: Alla V. Rudakova, et al.
Published: (2018-01-01)

Vaccination in Aged Care in Australia: A Retrospective Study of Influenza, Herpes Zoster, and Pneumococcal Vaccination
by: Stephen Wiblin, et al.
Published: (2025-07-01)

LOCAL ANTIBODY AND CELLULAR IMMUNE RESPONSES TO INFLUENZA INFECTION AND VACCINATION
by: G. D. Petukhova, et al.
Published: (2014-07-01)

INDUCTION OF LONG-TERM T AND B CELL MEMORY IMMUNITY TO INFLUENZA A VIRUS (H5N1) IN PERSONS VACCINATED WITH LIVE INFLUENZA A VACCINE (H5N2)
by: I. V. Losev, et al.
Published: (2017-08-01)

AVIDITY EVALUATION OF LOCAL IgA ANTIBODIES IN PERSONS IMMUNIZED WITH LIVE INFLUENZA VACCINE
by: S. A. Donina, et al.
Published: (2014-07-01)